AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17143189 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg daily
Number of subjects: 14
Study 15334195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 2 mg/day, po with CsA (8-10 mg/kg/day, po) and prednisone (0.5 mg/day, po)
Number of subjects: 90
Study 15334195 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/day, po with CsA (8-10 mg/kg/day, po) and prednisone (0.5 mg/day, po)
Number of subjects: 90
Study 15334195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 90
Study 15334195 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 90
Study 12488133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded hemodialyzer for 6 months
Number of subjects: 41
Study 12488133 — intervention group
Group type: COMPARATOR
Intervention: Regular hemodialyzer after switching from vitamin E-bonded hemodialyzer
Number of subjects: 41
Study 9830249 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathology (externalizing symptoms, internalizing symptoms)
Number of subjects: 216
Study 9830249 — intervention group
Group type: EXPERIMENTAL
Intervention: Socialization factors (peer influences, parental support, parental approval of use)
Number of subjects: 216
Study 9830249 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental support and control
Number of subjects: 216
Study 9830249 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing pathology
Number of subjects: 216
Study 9830249 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing symptoms, parental alcoholism, peer influences, parental support
Number of subjects: 216
Study 9830249 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing symptoms, internalizing symptoms, peer influences, parental approval of use
Number of subjects: 216
Study 7926110 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal ultrasonographic examination during stimulated cycles, controlled endometrial cycles, and natural cycles.
Number of subjects: 405
Study 2506754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg
Number of subjects: 6
Study 2506754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 2 mg
Number of subjects: 6
Study 2506754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg and 2 mg
Number of subjects: 6
Study 1098875 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day followed by 100 mg daily for a total of 7 days)
Number of subjects: 44
Study 1098875 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (250 mg 4 times daily for 7 days)
Number of subjects: 44
Study 31062295 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home, long-duration transcranial motor cortex stimulation (H-tDCS)
Number of subjects: 12
Study 31062295 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (20% of sessions)
Number of subjects: 12
Study 28767566 — intervention group
Group type: EXPERIMENTAL
Intervention: Shi-style cervical manipulations (SCM)
Number of subjects: 359
Study 28767566 — intervention group
Group type: COMPARATOR
Intervention: Mechanical cervical traction (MCT)
Number of subjects: 359
Study 26346874 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale (BBS)
Number of subjects: 33
Study 26346874 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s chair stand test (CST)
Number of subjects: 33
Study 26346874 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 m walking test
Number of subjects: 33
Study 26346874 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale (BBS) internal consistency
Number of subjects: 33
Study 23374010 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain rate between 0 and 3 months
Number of subjects: 12171
Study 23374010 — intervention group
Group type: EXPERIMENTAL
Intervention: Current weight and height
Number of subjects: 12171
Study 23374010 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain variables (except birth weight)
Number of subjects: 12171
Study 20093969 — intervention group
Group type: COMPARATOR
Intervention: DJ45-H (hurdle depth jump)
Number of subjects: 14
Study 20093969 — intervention group
Group type: COMPARATOR
Intervention: DJ45-T (target depth jump)
Number of subjects: 14
Study 19425819 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (static and dynamic tasks) twice a week for six weeks
Number of subjects: 24
Study 19425819 — intervention group
Group type: COMPARATOR
Intervention: Control group (same protocol without vibratory stimulus)
Number of subjects: 24
Study 17722826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at acute stage (1-10 days) at points Dicang (ST 4), Jiache (ST 6), Yangbai (GB 14), with less than 4 points selected on the face and shallow puncture, followed by electroacupuncture after 10 days.
Number of subjects: 52
Study 17722826 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with the same methods as the treatment group but without acupuncture at the acute stage.
Number of subjects: 52
Study 15022372 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based preventive intervention
Number of subjects: 2678
Study 12486439 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 52
Study 12486439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11477855 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 46
Study 11477855 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (AP)
Number of subjects: 46
Study 7855937 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS)
Number of subjects: 64
Study 7855937 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 64
Study 7855937 — intervention group
Group type: COMPARATOR
Intervention: Conventional digital rectal examination (DRE)
Number of subjects: 64
Study 2672065 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 48
Study 2672065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 mg)
Number of subjects: 48
Study 770365 — intervention group
Group type: EXPERIMENTAL
Intervention: nialamide + l-5-HTP
Number of subjects: 30
Study 770365 — intervention group
Group type: COMPARATOR
Intervention: nialamide
Number of subjects: 30
Study 31541633 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk model for predicting in-hospital mortality
Number of subjects: 56776
Study 31541633 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk model
Number of subjects: 56776
Study 31111697 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Convolutional Networks (FCN) model
Number of subjects: 900
Study 28040825 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM-training (five sessions)
Number of subjects: 264
Study 28040825 — intervention group
Group type: COMPARATOR
Intervention: Non-specific group training (five sessions)
Number of subjects: 264
Study 26541963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor Support by mentors with a visual impairment in combination with care-as-usual
Number of subjects: 120
Study 26541963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor Support by mentors without visual impairments in combination with care-as-usual
Number of subjects: 120
Study 26541963 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual only
Number of subjects: 120
Study 23433656 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.1 IU kg(‐1) day(‐1)
Number of subjects: 16
Study 23433656 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 22025856 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 70
Study 22025856 — intervention group
Group type: COMPARATOR
Intervention: Rupatadine
Number of subjects: 70
Study 19726399 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care (health education pamphlets, three sessions of individual health education and emotional support, two follow-up telephone counseling sessions)
Number of subjects: 122
Study 19726399 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 122
Study 17291931 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 50
Study 15089331 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic heart-rate model
Number of subjects: 15
Study 11318844 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 54
Study 11318844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Number of subjects: 54
Study 11318844 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 54
Study 9152683 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d beta-carotene and placebo for alpha-tocopherol
Number of subjects: 21
Study 9152683 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene plus 400 IU alpha-tocopherol for ten weeks
Number of subjects: 21
Study 9152683 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy Austrian subjects, n = 13)
Number of subjects: 21
Study 7686028 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (3000 ng infused into the graft)
Number of subjects: 83
Study 7686028 — intervention group
Group type: COMPARATOR
Intervention: Control (no iloprost infusion)
Number of subjects: 83
Study 2979675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost 100 micrograms
Number of subjects: 20
Study 2979675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost 200 micrograms
Number of subjects: 20
Study 2979675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost 400 micrograms
Number of subjects: 20
Study 2979675 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 20
Study 2979675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29493474 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE label on familiar snack foods
Number of subjects: 153
Study 29493474 — intervention group
Group type: COMPARATOR
Intervention: Control (no PACE label)
Number of subjects: 153
Study 29493474 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar snacks
Number of subjects: 153
Study 27260515 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% sleep restriction with an advanced wake-time
Number of subjects: 18
Study 27260515 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% sleep restriction with a delayed bedtime
Number of subjects: 18
Study 27260515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep architecture (polysomnography)
Number of subjects: 18
Study 27260515 — intervention group
Group type: COMPARATOR
Intervention: Control (habitual bed‐ and wake‐times)
Number of subjects: 18
Study 25187667 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.4g/day) for 7 days
Number of subjects: 21
Study 25187667 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg/day) from day 5 to day 7
Number of subjects: 21
Study 22208477 — intervention group
Group type: EXPERIMENTAL
Intervention: Liu Wei Di Huang Wan (LDW) 4.8 g (12 pills, 0.2 g/pill, twice daily) for 14 days
Number of subjects: 12
Study 22208477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20061436 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (combined aerobic/resistive exercise training)
Number of subjects: 16
Study 20061436 — intervention group
Group type: COMPARATOR
Intervention: Control group (strict 60-day bed rest)
Number of subjects: 16
Study 17287406 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 179
Study 17287406 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 179
Study 17287406 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 179
Study 17287406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low free triiodothyronine
Number of subjects: 179
Study 17287406 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated thyrotropin receptor antibody
Number of subjects: 179
Study 17287406 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone state (including subclinical thyrotoxicosis)
Number of subjects: 179
Study 15640980 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized wrist splints worn at night for 6 weeks
Number of subjects: 0
Study 15640980 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic education alone
Number of subjects: 0
Study 12375297 — intervention group
Group type: EXPERIMENTAL
Intervention: CACE estimation approach
Number of subjects: 0
Study 9989193 — intervention group
Group type: EXPERIMENTAL
Intervention: Single chamber atrial pacing
Number of subjects: 225
Study 9989193 — intervention group
Group type: COMPARATOR
Intervention: Single chamber ventricular pacing
Number of subjects: 225
Study 8527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) plus lymphoblastoid interferon (IFN)-alpha
Number of subjects: 402
Study 8527074 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) alone
Number of subjects: 402
Study 1573098 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care preoperative teaching programme
Number of subjects: 0
Study 4040337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 155
Study 4040337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 155
Study 4040337 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 155
Study 4040337 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral myringotomy and ventilating tube insertion
Number of subjects: 155
Study 29353440 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing Kaledo over 20 sessions
Number of subjects: 1313
Study 29353440 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1313
Study 27417177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage (IM)
Number of subjects: 30
Study 27417177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water massage (TWM)
Number of subjects: 30
Study 27417177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone rest (PR)
Number of subjects: 30
Study 26637849 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐impregnated intrauterine system (LNG‐IUS)
Number of subjects: 141
Study 26637849 — intervention group
Group type: COMPARATOR
Intervention: Oral progestin (10 mg medroxyprogesterone acetate (MPA) taken continuously)
Number of subjects: 141
Study 26637849 — intervention group
Group type: COMPARATOR
Intervention: Oral progestin (10 mg MPA taken 10 days per cycle for six months)
Number of subjects: 141
Study 23073567 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless fluid monitoring using OptiVol alerts and ICD remote monitoring (RM)
Number of subjects: 180
Study 23073567 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 180
Study 20810107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (GnRH antagonist)
Number of subjects: 0
Study 20810107 — intervention group
Group type: COMPARATOR
Intervention: Control (without cetrorelix)
Number of subjects: 0
Study 19178095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (InT) performed within 24 hours
Number of subjects: 25
Study 19178095 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CoT) with one treatment session a week for 4 weeks
Number of subjects: 25
Study 16601570 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 3
Study 16601570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 12975252 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-assisted PCI
Number of subjects: 988
Study 12975252 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 988
Study 12975252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CABG and stent-assisted PCI
Number of subjects: 988
Study 11069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 101
Study 11069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 101
Study 11069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 101
Study 11069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus supportive psychotherapy
Number of subjects: 101
Study 9497696 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA using propofol
Number of subjects: 0
Study 9497696 — intervention group
Group type: COMPARATOR
Intervention: Conventional thiopentone/isoflurane/nitrous oxide technique
Number of subjects: 0
Study 2295232 — intervention group
Group type: EXPERIMENTAL
Intervention: RRKTT (oscillating bed)
Number of subjects: 106
Study 2295232 — intervention group
Group type: COMPARATOR
Intervention: Conventional bed (control)
Number of subjects: 106
Study 453892 — intervention group
Group type: EXPERIMENTAL
Intervention: SEUV TG (suberythemogenic ultraviolet phototherapy with tar gel)
Number of subjects: 0
Study 453892 — intervention group
Group type: COMPARATOR
Intervention: Modified Goeckerman (erythemogenic tar gel phototherapy regimen)
Number of subjects: 0
Study 453892 — intervention group
Group type: COMPARATOR
Intervention: Tar gel alone
Number of subjects: 0
Study 453892 — intervention group
Group type: COMPARATOR
Intervention: SEUV irradiation following application of gel vehicle
Number of subjects: 0
Study 31323562 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) using radiofrequency ultrasound images
Number of subjects: 131
Study 31323562 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound techniques
Number of subjects: 131
Study 28376855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 33
Study 28376855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 24983350 — intervention group
Group type: EXPERIMENTAL
Intervention: MVG 1.3% once daily for 1 day
Number of subjects: 255
Study 24983350 — intervention group
Group type: EXPERIMENTAL
Intervention: MVG 1.3% once daily for 3 days
Number of subjects: 255
Study 24983350 — intervention group
Group type: EXPERIMENTAL
Intervention: MVG 1.3% once daily for 5 days
Number of subjects: 255
Study 24983350 — intervention group
Group type: COMPARATOR
Intervention: MVG 0.75% once daily for 5 days
Number of subjects: 255
Study 23183264 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety symptoms
Number of subjects: 250
Study 23183264 — intervention group
Group type: EXPERIMENTAL
Intervention: Early change in anxiety
Number of subjects: 250
Study 23183264 — intervention group
Group type: COMPARATOR
Intervention: Baseline social stressors
Number of subjects: 250
Study 23183264 — intervention group
Group type: COMPARATOR
Intervention: Early change in social stressors
Number of subjects: 250
Study 22205930 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination
Number of subjects: 16402
Study 22205930 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521)
Number of subjects: 16402
Study 22205930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16402
Study 19234890 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffman compact II fixator (H group)
Number of subjects: 75
Study 19234890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynawrist fixator (D group)
Number of subjects: 75
Study 16403097 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 18
Study 16403097 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 18
Study 12928870 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidacloprid 10% w/v / Permethrin 50% w/v combination
Number of subjects: 0
Study 12928870 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study 10945514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hydrocodone 7.5 mg and ibuprofen 200 mg (2-tablet dose)
Number of subjects: 469
Study 10945514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hydrocodone 7.5 mg and ibuprofen 200 mg (1-tablet dose)
Number of subjects: 469
Study 10945514 — intervention group
Group type: COMPARATOR
Intervention: Combination codeine 30 mg and acetaminophen 300 mg (2-tablet dose)
Number of subjects: 469
Study 9112450 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week radiotherapy schedule (66 Gy in 2 Gy/fraction)
Number of subjects: 40
Study 9112450 — intervention group
Group type: COMPARATOR
Intervention: 4-week radiotherapy schedule (66 Gy in 2 Gy/fraction)
Number of subjects: 40
Study 8495454 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg plus paracetamol 1 g
Number of subjects: 46
Study 8495454 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 30 mg plus paracetamol 1 g
Number of subjects: 46
Study 8495454 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g alone
Number of subjects: 46
Study 3545152 — intervention group
Group type: COMPARATOR
Intervention: 4',6-Dichloroflavan (40 mg; 5 times per day) administered intranasally as a 5% w/v aqueous suspension for 5 doses before and 21 doses after rhinovirus challenge.
Number of subjects: 49
Study 3545152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study 31728671 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (attending surgeon performed all four cardinal steps)
Number of subjects: 12
Study 31728671 — intervention group
Group type: COMPARATOR
Intervention: Group B (trainee involved in at least one cardinal step)
Number of subjects: 12
Study 31728671 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (attending performs the whole case)
Number of subjects: 12
Study 31728671 — intervention group
Group type: COMPARATOR
Intervention: Group D (trainee performed at least one non-cardinal step)
Number of subjects: 12
Study 28872388 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight/Normal weight
Number of subjects: 61
Study 28872388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/Obese
Number of subjects: 61
Study 28872388 — intervention group
Group type: COMPARATOR
Intervention: Normal weight/Underweight
Number of subjects: 61
Study 27758944 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once daily for 90 days
Number of subjects: 104